GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

ToolGen 199800.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

30,150

+6.91%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩1.31bn

FY2016FY2025

Net income

−₩36.76bn

FY2016FY2025

Free cash flow

−₩20.67bn

FY2016FY2025

Shareholders' equity

₩55.85bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩1.31bn₩891.0m₩1.10bn₩743.5m₩1.60bn₩713.1m₩1.13bn₩1.16bn₩3.34bn₩1.54bn
Research and development₩7.15bn₩6.84bn₩6.75bn₩6.30bn₩5.45bn₩4.20bn————
Operating income−₩23.28bn₩6.41bn−₩17.15bn−₩19.39bn−₩20.74bn−₩14.97bn−₩16.13bn−₩8.33bn−₩4.06bn−₩3.26bn
Net income−₩36.76bn₩6.23bn−₩42.34bn−₩18.18bn−₩20.69bn−₩14.88bn−₩15.78bn−₩8.06bn−₩4.34bn−₩3.02bn
Diluted earnings per share-4,033.21729.16-5,348.16-2,305.99-2,636.01-2,214.54-2,422.78-1,258.03-748.31-522.12

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩61.65bn₩75.48bn₩93.45bn₩75.43bn₩87.62bn₩32.41bn₩29.87bn₩38.74bn₩15.16bn₩18.28bn
Cash and short-term investments—₩48.96bn₩64.65bn₩52.70bn₩72.25bn₩19.85bn₩21.70bn₩31.98bn₩9.01bn₩13.98bn
Total liabilities₩5.80bn₩17.04bn₩63.36bn₩4.96bn₩2.95bn₩2.52bn₩3.10bn₩1.75bn₩2.17bn₩1.39bn
Debt—₩156.4m₩105.5m₩20.0m₩93.0m₩135.5m₩121.8m—₩800.0m₩800.0m
Shareholders' equity₩55.85bn₩58.44bn₩30.09bn₩70.47bn₩84.66bn₩29.89bn₩26.77bn₩36.99bn₩12.99bn₩16.89bn
Shares outstanding9m9m8m8m8m7m7m6m6m6m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−₩20.22bn−₩16.46bn−₩14.91bn−₩14.99bn−₩14.83bn−₩10.07bn−₩9.97bn−₩6.29bn−₩1.79bn−₩3.36bn
Capital spending−₩451.3m−₩534.9m−₩6.68bn−₩5.38bn−₩617.7m−₩2.37bn−₩801.6m−₩434.7m−₩3.29bn−₩274.0m
Free cash flow−₩20.67bn−₩16.99bn−₩21.59bn−₩20.37bn−₩15.45bn−₩12.44bn−₩10.78bn−₩6.73bn−₩5.07bn−₩3.63bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩487.2m₩390.7m₩404.2m₩630.5m₩185.2m₩129.1m₩169.6m₩441.1m
Operating income−₩6.89bn−₩4.59bn−₩6.94bn−₩5.42bn−₩6.29bn−₩4.61bn−₩5.68bn−₩5.00bn
Net income−₩6.78bn−₩4.41bn−₩22.48bn−₩5.45bn−₩4.39bn−₩4.44bn₩22.53bn−₩5.16bn
Diluted earnings per share-741.55-482.71-2,466.28-614.24-503.62-519.452,636.20-649.77
Cash from operations−₩5.42bn−₩4.50bn−₩6.81bn−₩5.02bn−₩4.49bn−₩3.90bn−₩16.46bn−₩11.56bn
Capital spending−₩729.0m−₩1.10bn−₩224.0m−₩59.0m−₩145.0m−₩21.0m−₩534.0m−₩362.0m
Free cash flow−₩6.15bn−₩5.61bn−₩7.03bn−₩5.08bn−₩4.64bn−₩3.92bn−₩16.99bn−₩11.93bn
Total assets₩51.31bn₩57.28bn₩61.65bn₩68.38bn₩73.16bn₩71.45bn₩75.48bn₩81.78bn
Cash and short-term investments—————₩45.30bn₩48.96bn₩53.93bn
Debt—————₩74.9m₩116.7m₩148.7m
Shareholders' equity₩46.50bn₩53.17bn₩55.85bn₩53.51bn₩54.64bn₩54.00bn₩58.44bn₩14.90bn

Financial ratios

Data as of 1 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating margin-1782.0%719.2%-1553.9%-2607.5%-1298.5%-2098.7%—
Net margin-2814.1%699.5%-3837.2%-2444.9%-1295.5%-2086.9%—
Return on equity-65.8%10.7%-140.7%-25.8%-24.4%-49.8%—
Return on assets-59.6%8.3%-45.3%-24.1%-23.6%-45.9%—
Revenue growth46.6%-19.3%48.4%-53.5%124.0%-36.6%—
Earnings growth-689.9%-114.7%132.9%-12.2%39.0%-5.7%—
Current ratio7.45x3.22x37.40x14.69x38.03x19.25x—
Debt to equity—0.00x2.00x0.00x0.00x0.00x0.00x
Equity ratio90.6%77.4%32.2%93.4%96.6%92.2%—
Interest coverage-21.48x2.48x-40.04x-683.20x-709.01x-464.94x—
R&D as a share of sales547.6%767.6%611.5%846.9%341.1%589.2%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue20.7%12.9%—
Operating income6.3%9.2%—
Net income26.5%19.8%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-14.552.5-13.1-23.8-34.4-50.1-22.1-79.5-77.1-53.1
Price to sales408.9366.9——445.3—310.3—100.3104.1

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.